Skusa Christopher, Weber Marc-André, Böttcher Sebastian, Thierfelder Kolja M
Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, Rostock University Medical Center, Rostock, Germany.
Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
Rofo. 2020 Jul;192(7):657-668. doi: 10.1055/a-1091-8897. Epub 2020 Mar 26.
The rapid progress in oncology research requires numerous new scientific publications. This article aims to provide an overview of criteria-based imaging and response evaluation of lymphoma according to the current status of knowledge. In fact, common criteria for evaluating data, especially imaging response evaluation, are essential for comparability of studies. While criteria-based classifications of solid tumors have been established for some time, there are now increasing classifications of lymphoma diseases. The purpose of this review is to describe the development of criteria-based evaluation of lymphoma diseases with a special focus on imaging up to current guidelines.
Literature review based on PubMed including the languages English and German was performed. This review article includes the most important criteria-based response evaluations of lymphoma published between January 1999 and July 2019.
The two latest classifications of response evaluation of lymphoma are: The Lugano classification, which has been steadily developed over the past 20 years and has been specially adapted to technical progress, as well as the evaluation method RECIL (Response Evaluation Criteria In Lymphoma), which is based on the RECIST (Response Evaluation Criteria in Solid Tumors) classification already established for solid tumors. Significant imaging components of both classifications are the anatomical measurement and measurement of the metabolic response of the manifestation of lymphoma using positron emission tomography (PET/CT).
· Standardized criteria-based response evaluations are essential for the objective and comparable analysis of new drugs for the treatment of lymphoma diseases.. · The latest classification RECIL has significantly simplified treatment evaluation and has established a better comparability to the therapeutic evaluation of solid tumors according to RECIST.. · Further studies will show the most appropriate classifications depending on study settings..
· Skusa C, Weber M, Böttcher S et al. Criteria-Based Imaging and Response Evaluation of Lymphoma 20 Years After Cheson: What is New?. Fortschr Röntgenstr 2020; 192: 657 - 667.
肿瘤学研究的快速发展需要大量新的科学出版物。本文旨在根据当前的知识状况，对基于标准的淋巴瘤成像和反应评估进行概述。事实上，评估数据的通用标准，尤其是成像反应评估，对于研究的可比性至关重要。虽然基于标准的实体瘤分类已经确立了一段时间，但现在淋巴瘤疾病的分类也越来越多。本综述的目的是描述基于标准的淋巴瘤疾病评估的发展，特别关注直至当前指南的成像方面。
基于PubMed进行文献综述，包括英语和德语语言的文献。这篇综述文章涵盖了1999年1月至2019年7月期间发表的关于淋巴瘤的最重要的基于标准的反应评估。
淋巴瘤反应评估的两个最新分类是：卢加诺分类，它在过去20年中不断发展，并特别适应了技术进步；以及评估方法RECIL（淋巴瘤反应评估标准），它基于已为实体瘤确立的RECIST（实体瘤反应评估标准）分类。这两种分类的重要成像组成部分是淋巴瘤表现的解剖学测量和使用正电子发射断层扫描（PET/CT）的代谢反应测量。
· 基于标准的标准化反应评估对于客观且可比地分析治疗淋巴瘤疾病的新药至关重要。· 最新的分类RECIL显著简化了治疗评估，并与根据RECIST进行的实体瘤治疗评估建立了更好的可比性。· 进一步的研究将根据研究设置显示最合适的分类。
· Skusa C, Weber M, Böttcher S等。Cheson提出淋巴瘤基于标准的成像和反应评估20年后：有哪些新进展？。Fortschr Röntgenstr 2020; 192: 657 - 667。
